Canada approves GW Pharma drug in cannabis first

Canada became the first country in the world to approve a cannabis-derived medicine on Tuesday when it gave a green light to a mouth spray developed by Britain’s GW Pharmaceuticals Plc .
The go-ahead had been expected after Canadian regulators said last December that Sativex, which is sprayed under the tongue, qualified to be considered for approval.
But the news still boosted GW shares as much as 14 percent, reflecting the importance of the product to the small biotechnology firm.
Sativex, which is designed to help patients with multiple sclerosis (MS), will be marketed in Canada by Germany’s Bayer AG and is likely to launched in May, according to GW Pharma Executive Chairman Geoffrey Guy.
Reuters AlertNet – Canada approves GW Pharma drug in cannabis first

Comments are closed.